Lisata Therapeutics has acquired Marea Therapeutics, a biotech focused on cardioendocrine diseases, through a stock-for-stock deal. The transaction includes a private placement expected to raise about $225 million, which Lisata will use to fund clinical trials for Marea's drug candidates targeting severe hypertriglyceridemia and acromegaly. These trials are set to report results in late 2027. Post-acquisition, Marea's shareholders will hold the majority stake, while Lisata's prior shareholders and new investors will own smaller portions. This move expands Lisata's focus and resources toward advancing important cardioendocrine treatments.
Lisata Therapeutics' acquisition of Marea Therapeutics is the subject here, with Pluang's Health-sector market data providing context. Of 91 priced Health-sector US stocks tradable on Pluang, 65 rose and 26 fell today. Notable movers include DNA at USD 7.77 (+10.06%), CRSP at USD 56.74 (+8.69%, with 35% Sell / 65% Buy order activity), and RXRX at USD 3.46 (+8.62%, with 0% Sell / 100% Buy order activity). These figures are as of Sep 17, 2026 23:42 WIB.
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
Venture Global is expanding its power business by securing deals with GE Vernova and Baker Hughes to build natural gas-fired power plants for data centers, aiming to meet the high electricity demands of AI systems. The company also plans to grow its ...
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
